Standard Biotools INC Form 4 insider transactions

Michael Egholm, CEO of Standard BioTools Inc., disposed of 102,564 shares of common stock on April 8, 2024, to cover tax obligations related to vesting performance-based restricted stock units.

CEO Michael Egholm reports acquisition and vesting of Standard BioTools stock, including shares received from the SomaLogic merger and performance-based restricted stock units.

Hanjoon Alex Kim, Chief Operating Officer of Standard BioTools Inc., reports transactions involving restricted stock units (RSUs) and common stock.

Casdin Partners and related entities acquire a substantial amount of Standard BioTools Inc. common stock and dispose of convertible preferred stock.

Casdin Partners and related entities report acquiring additional shares of Standard BioTools Inc. (LAB) common stock, increasing their total holdings.